# Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma

> **NCT06198465** · PHASE2 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Adebrelimab
- Esophageal Cancer
- Perioperative Period

## Interventions

- **DRUG:** adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil

## Key facts

- **NCT ID:** NCT06198465
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06198465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06198465, "Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06198465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*